BioVentrix Announces First Patient Enrolled in the U.S. arm of IDE Study of the Revivent TC(TM) TransCatheter Ventricular Enhancement Treatment

SAN RAMON, Calif., and PITTSBURGH, Pa., Oct. 4, 2017 -- (Healthcare Sales & Marketing Network) -- BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced enrollment of the first patient ... Devices, Interventional, Cardiology BioVentrix, Revivent TC, TransCatheter, Ventricular Enhancement

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2043038

Source: HSMN NewsFeed - October 4, 2017 Category: Pharmaceuticals Source Type: news